Aristea Therapeutics
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
Aristea developed therapeutic programs targeting autoimmune diseases.
02 / Aristea Therapeutics FAILURE REASONS
Failure reasons
Safety findings during ongoing mid-stage trials prompted the company to stop RIST4721 to protect patients. After reviewing strategic alternatives, the board decided that the business should be wound down and dissolved.
03 / EVENT HISTORY
Events in the structured record
- Drug development discontinued
On 10 February the company announced termination of RIST4721 because of safety findings.
- Wind-down and dissolution decision
The same announcement disclosed the board’s decision to conclude operations and dissolve the company.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
RIST4721 progressed into mid-stage trials
- 02
Safety findings emerged
- 03
Development stopped to protect patients
- 04
Board chose business wind-down and dissolution